Durable clinical and metabolic response to Trastuzumab Deruxtecan in heavily Pretreated male HER2-low metastatic breast cancer: a case report
{{output}}
Background: Male breast cancer (MBC), accounting for < 1% of all breast malignancies, remains underrepresented in clinical trials evaluating human epidermal growth factor receptor 2 (HER2)-targeted therapies. Most MBCs are hormon... ...
